Journal for ImmunoTherapy of Cancer · 2023 · 85 citations · 40 references
We elucidate an adaptive immunosuppression mechanism rendering resistance to PARPi in BRCA1-mutant ovarian tumors. This is mediated by enrichment of protumor TAMs propelled by PARPi-induced STAT3 activation in tumor cells. We also provide a new strategy to reshape the immunosuppressive TME with STING agonists and overcome PARPi resistance in ovarian cancer.
40
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.5K citations
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt et al. · New England Journal of Medicine · 2016 · 2.4K citations · Full text
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi et al. · New England Journal of Medicine · 2020 · 2.1K citations · Full text
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote et al. · New England Journal of Medicine · 2019 · 2.1K citations · Full text